DIA Global 2018: Value Pricing Bootcamp: A Crash Course in How to Use Real World Evidence to Better Measure Outcomes and Evaluate New Innovative Therapies
24 June 2018 1:00 PM – 4:30 PM
Boston Convention and Exhibition Center
This Short Course will outline how best to harness RWE to better understand the price, value, and impact of next generation therapies.
Instructors
![luca-pani-6Oct-100×100](https://vitaltransformation.com/wp-content/uploads/2018/05/luca-pani-6Oct-100x100.jpg)
Luca Pani
University of Miami
Former Director General Italian Medicines Agency (AIFA)
![Duane-sq](https://vitaltransformation.com/wp-content/uploads/2015/04/Duane-sq.jpg)
Duane Schulthess
Managing Director
Vital Transformation
Contributors
![Amr_Makady100X100](https://vitaltransformation.com/wp-content/uploads/2018/05/Amr_Makady100X100.jpeg)
Amr Makady
Pharmacoeconomics Advisor
Zorginstituut Nederland
![Brian1](https://vitaltransformation.com/wp-content/uploads/2014/06/Brian1.jpg)
Brian Rothman
Senior Director, Office of the Chief Health Information Officer
Vanderbilt University
![Anna_Ludlow_100x100](https://vitaltransformation.com/wp-content/uploads/2014/06/Anna_Ludlow_100x100.jpg)
Anna Ludlow
Project Manager
Vital Transformation
![Raffoul_Julian](https://vitaltransformation.com/wp-content/uploads/2018/05/Raffoul_Julian.jpg)
Julian Raffoul
Clinical Scientist
Nashville Biosciences
![daniel-gassull](https://vitaltransformation.com/wp-content/uploads/2014/05/daniel-gassull.jpg)
Daniel Gassull
Research Partner
Vital Transformation
The session will feature:
- Pricing and value case studies based on current clinical therapies such as CAR-T, IO Checkpoint, and HEP C
- Interactive workshop discussions on various payment options such as annuity, up front, or pay on performance
- An overview of the Italian outcomes system of reimbursement and how it has impacted price and access
- Real-time cost and outcomes modeling to test and aid discussions on various options to stakeholders
- Horizon scanning discussions on the impact of cures in areas such as Duchene Muscular Dystrophy, Viral Therapies, or Alzheimer’s which may arrive in 3-5 years: How can we plan now? What should we do differently?
Learning Objectives: This session will address the pricing, value, and access challenges being caused by highly effective targeted therapies such as IO Checkpoint, CAR-T, and Gene Therapies.